AU Patent

AU2006278627B2 — Thiazolopyrimidine kinase inhibitors

Assigned to Janssen Pharmaceutica NV · Expires 2011-08-18 · 15y expired

What this patent protects

The present invention is directed to novel thiazolopyrimidine compounds of Formula (I) or a form or composition thereof, and the use thereof as inhibitors of ATP-protein kinase interactions.

USPTO Abstract

The present invention is directed to novel thiazolopyrimidine compounds of Formula (I) or a form or composition thereof, and the use thereof as inhibitors of ATP-protein kinase interactions.

Drugs covered by this patent

Patent Metadata

Patent number
AU2006278627B2
Jurisdiction
AU
Classification
—
Expires
2011-08-18
Drug substance claim
No
Drug product claim
No
Assignee
Janssen Pharmaceutica NV
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.